Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Non-Current Deferred Tax Liability (2022 - 2023)

Historic Non-Current Deferred Tax Liability for Zentalis Pharmaceuticals (ZNTL) over the last 2 years, with Q4 2023 value amounting to $10.3 million.

  • Zentalis Pharmaceuticals' Non-Current Deferred Tax Liability fell 3107.33% to $10.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $10.3 million, marking a year-over-year decrease of 3107.33%. This contributed to the annual value of $10.3 million for FY2023, which is 3107.33% down from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Non-Current Deferred Tax Liability stood at $10.3 million for Q4 2023, which was down 3107.33% from $756000.0 recorded in Q1 2023.
  • Over the past 5 years, Zentalis Pharmaceuticals' Non-Current Deferred Tax Liability peaked at $15.0 million during Q4 2022, and registered a low of $756000.0 during Q1 2023.